Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.24 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1676
    +0.0024 (+0.21%)
     

  • GBP/USD

    1.2576
    +0.0029 (+0.23%)
     

  • Bitcoin GBP

    51,104.71
    +455.12 (+0.90%)
     

  • CMC Crypto 200

    1,382.60
    +69.98 (+5.33%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +449.98 (+1.18%)
     

  • CRUDE OIL

    78.97
    +0.86 (+1.10%)
     

  • GOLD FUTURES

    2,328.60
    +20.00 (+0.87%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

  • HANG SENG

    18,578.30
    +102.38 (+0.55%)
     

  • DAX

    18,166.04
    +164.44 (+0.91%)
     

  • CAC 40

    8,020.91
    +63.34 (+0.80%)
     

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024

Pulmonx Corporation
·1-min read
Pulmonx Corporation
Pulmonx Corporation

REDWOOD CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 1, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com